Saturday, 18 August 2018

Announcement

GENERAL: TRU: TruScreen2 Sales to China commence following CFDA Approval

21 Dec 2017 08:30NZX
NZX and Media Release

21 December, 2017

NZX Limited
WELLINGTON

TruScreen2 Sales to China commence following CFDA Approval

Cervical cancer screening technology company, TruScreen Limited (NZAX: TRU)
advises that, following on from receipt of China Food and Drug Administration
(CFDA) approval for its new TruScreen2 device, as announced on 4 December
2017,  it has now received an initial payment of NZ$188,000 against initial
orders from its Chinese distributor.

TruScreen chair, Robert Hunter, said "The establishment of a market for
TruScreen2 in China has been a major focus for the company and, as previously
announced, there has been strong interest in TruScreen2 pending CFDA
approval.  The company is now producing consoles at its maximum capacity to
meet current and anticipated orders from China which is our largest target
market."

ENDS

For more information visit www.truscreen.com or contact:
Martin Dillon
TruScreen Chief Executive Officer
Email: martindillon@truscreen.com

Media Liaison
Jackie Ellis
Email: jackie@ellisandco.co.nz
Phone: +64 27 246 2505

About TruScreen:
TruScreen''s real time cervical cancer technology utilises a digital wand
which is placed on the surface of the cervix to measure electrical and
optical signals from the surrounding tissue. A sophisticated proprietary
algorithm framework distinguishes between normal and abnormal (cancerous and
precancerous) tissue to identify precancerous change, or cervical
intraepithelial neoplasia (CIN).  A Single Use Sensor (SUS) is used for each
patient to protect against cross-infection.
End CA:00312270 For:TRU    Type:GENERAL    Time:2017-12-21 08:30:53
Views: 49
TruScreen Limited Ordinary Shares
 0.1850 Change:
0.01
2.63%
 
Open:0.1900 
High:0.1900 
Low:0.1900 
Volume:22,054 
Last Traded:07/02/18 09:15:21 
Bid:0.1850 
Ask:0.1850 
52-Wk High:0.2300 
52-Wk Low:0.1200